MSC Therapy in Korea |  Gangnam JS Hospital

Here’s a concise overview of allogenic MSC (mesenchymal stem cell) therapy at Gangnam JS Hospital in Seoul, Republic of Korea — focusing specifically on what you should know about the treatment, its basis, and clinical relevance:

🧬 What Type of MSC Therapy They Provide

Allogenic MSC therapy at Gangnam JS Hospital is generally delivered using umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) — a type of allogenic (donor-derived) mesenchymal stem cell product used for cartilage regeneration rather than from the patient’s own tissue.

  • The primary product used is Cartistem®, manufactured by Medipost. This is an allogeneic umbilical cord blood-derived MSC therapy formulated with hyaluronic acid for direct implantation into cartilage defects. It’s used mainly for degenerative knee conditions (e.g., osteoarthritis) to stimulate cartilage repair.
  • hUCB-MSCs are non-invasive to collect, can be expanded in culture, and have low immunogenicity, meaning they are less likely to trigger immune rejection compared with other cell sources.

🦵 Clinical Use — What They Treat

At this hospital, allogenic MSC therapy is most commonly applied for:

Degenerative knee osteoarthritis and cartilage defects, where:

  • The hUCB-MSC product is implanted into areas of cartilage damage to promote regeneration of hyaline-like cartilage.
  • The goal is to reduce pain, improve joint function, and delay or avoid total knee replacement surgery by restoring cartilage rather than just treating symptoms.

This treatment approach is positioned as a regenerative alternative to traditional cartilage surgery or joint replacement.

📊 Evidence & Adoption

  • Clinical use of CARTISTEM® at this hospital has grown significantly; reports mention that over 3,000 procedures using umbilical cord blood-derived MSC therapy have been performed there — indicating substantial institutional experience with this specific allogenic MSC technique.
  • Research literature (not specific to this hospital but relevant to the modality) supports hUCB-MSC cartilage treatments as safe and efficacious with regenerative outcomes in osteoarthritis and large cartilage defects, with improvements documented in functional scores and imaging outcomes.

📍 Practical Notes if Considering Treatment

  • Consultation required: Practical eligibility (age, severity, joint alignment, activity level) affects whether allogenic MSC therapy is suitable.
  • Not a universal cure: While promising, MSC implantation is a specific regenerative intervention for cartilage loss and is not broadly indicated for all joint or systemic conditions.

Contact information for appointments or international patient support is available via the hospital’s website or phone.